

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders highlighted that non-clear cell RCC patients or patients with hereditary RCC currently have an unmet need for an effective adjuvant treatment. They also noted equality of access to the clinical trial/drug treatment on the NHS/CDF regardless of where the patient lives

Stakeholders also noted that this treatment may only be suitable for those who can travel to a hospital for infusion thus excluding those who are not mobile or otherwise unable to travel (social or economic reasons). This may have particular impact on those in rural areas

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

An unmet need does not meet the definition protected characteristics therefore not an equality consideration. But the committee should consider if there is an overlap between those with non-clear cell RCC and any protected characteristics for a potential equality issue.

Socioeconomic status is not a protected characteristic under the equalities act but there is a duty for fairness. Equality of access is a potential equality issue and in a light of a positive recommendation might rise to indirect discrimination. The committee should be mindful of this potential issue, however, access and implementation are unlikely to be addressed within a

committee recommendation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** H Edwards

**Date:** 31/08/2021